Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Bluebird Bio ( (BLUE) ) is now available.
On June 2, 2025, Bluebird Bio announced the completion of its acquisition by Carlyle and SK Capital, marking a significant shift in its operational and strategic direction. The acquisition, which involved a tender offer and merger, resulted in Bluebird Bio’s delisting from Nasdaq and becoming an indirect wholly owned subsidiary of Carlyle and SK Capital. The new management team, led by CEO David Meek, is focused on expanding manufacturing capacity and improving access to Bluebird’s gene therapies. This acquisition provides Bluebird with substantial capital to enhance its commercial delivery of gene therapies, aiming to meet rising demand and drive operational excellence.
The most recent analyst rating on (BLUE) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Bluebird Bio stock, see the BLUE Stock Forecast page.
Spark’s Take on BLUE Stock
According to Spark, TipRanks’ AI Analyst, BLUE is a Underperform.
Bluebird Bio’s overall score reflects significant financial challenges, including unprofitable operations and negative equity. While technical analysis shows short-term momentum, long-term trends are less favorable. The negative P/E ratio underscores valuation concerns, and the lack of a dividend yield makes it less attractive for income investors.
To see Spark’s full report on BLUE stock, click here.
More about Bluebird Bio
Bluebird Bio is a commercial-stage biotherapeutics company focused on developing and delivering gene therapies for severe genetic diseases. The company has over a decade of scientific leadership in gene therapy and offers three FDA-approved therapies for sickle cell disease, ß-thalassemia, and cerebral adrenoleukodystrophy. Bluebird Bio is headquartered in Somerville, Massachusetts.
Average Trading Volume: 571,532
Technical Sentiment Signal: Sell
Current Market Cap: $48.67M
For detailed information about BLUE stock, go to TipRanks’ Stock Analysis page.